<p>在今天發佈的一份報告中，巴克萊的 Eliana Merle 維持了對 Madrigal Pharmaceuticals 的買入評級，目標價為 964.00 美元。</p>
<h3>在 TipRanks 上享受 55% 的折扣</h3>
<ul>
<li>解鎖對沖基金級別的數據和強大的投資工具，以做出更聰明、更精準的決策</li>
<li>發現表現優異的股票投資理念，並升級到市場領先者的投資組合，使用智能投資者精選</li>
</ul>
<p>根據 TipRanks，Merle 是一位 3 星分析師，平均回報率為 3.8%，成功率為 41.22%。Merle 覆蓋醫療保健行業，專注於 Alnylam Pharma、BridgeBio Pharma 和 BioMarin Pharmaceutical 等股票。</p>
<p>除了巴克萊，Madrigal Pharmaceuticals 還在昨天的報告中獲得了 H.C. Wainwright 的 Andrew Fein 的買入評級。然而，在同一天，美國銀行證券重申了對 Madrigal Pharmaceuticals（NASDAQ: MDGL）的持有評級。</p>

Madrigal制藥

標普生物技術 ETF - SPDR

動態生物技術與基因組 ETF - Invesco

標普生物技術 3 倍做多 - Direxion

醫療業 ETF - SPDR

生物科技 ETF - VanEck Vectors

紐交所高增長板生物技術指數 ETF - First Trust

納斯達克生物科技指數 ETF - iShares Nasdaq

醫藥突破 ETF - ALPS

<p>巴克萊分析師 Eliana Merle 對 Madrigal Pharmaceuticals (MDGL) 維持了買入評級，目標價為 964.00 美元。Merle 是一位 3 星分析師，平均回報率為 3.8%，成功率為 41.22%。此外，H.C. Wainwright 的 Andrew Fein 也對該公司發佈了買入評級，而美國銀行證券在同一天重申了持有評級</p>

<p>In a report released today, Eliana Merle from Barclays maintained a Buy rating on Madrigal Pharmaceuticals, with a price target of $964.00.</p>
<div class="lb-trans"><p>在今天發佈的一份報告中，巴克萊的 Eliana Merle 維持了對 Madrigal Pharmaceuticals 的買入評級，目標價為 964.00 美元。</p>
</div><h3>Claim 55% Off TipRanks</h3>
<div class="lb-trans"><h3>在 TipRanks 上享受 55% 的折扣</h3>
</div><ul>
<li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions</li>
<li>Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks</li>
</ul>
<div class="lb-trans"><ul>
<li>解鎖對沖基金級別的數據和強大的投資工具，以做出更聰明、更精準的決策</li>
<li>發現表現優異的股票投資理念，並升級到市場領先者的投資組合，使用智能投資者精選</li>
</ul>
</div><p>According to TipRanks, Merle is a 3-star analyst with an average return of 3.8% and a 41.22% success rate. Merle covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, BridgeBio Pharma, and BioMarin Pharmaceutical.</p>
<div class="lb-trans"><p>根據 TipRanks，Merle 是一位 3 星分析師，平均回報率為 3.8%，成功率為 41.22%。Merle 覆蓋醫療保健行業，專注於 Alnylam Pharma、BridgeBio Pharma 和 BioMarin Pharmaceutical 等股票。</p>
</div><p>In addition to Barclays, Madrigal Pharmaceuticals also received a Buy from H.C. Wainwright’s Andrew Fein in a report issued yesterday. However, on the same day, Bank of America Securities reiterated a Hold rating on Madrigal Pharmaceuticals (NASDAQ: MDGL).</p>
<div class="lb-trans"><p>除了巴克萊，Madrigal Pharmaceuticals 還在昨天的報告中獲得了 H.C. Wainwright 的 Andrew Fein 的買入評級。然而，在同一天，美國銀行證券重申了對 Madrigal Pharmaceuticals（NASDAQ: MDGL）的持有評級。</p>
</div>

Madrigal Pharmaceuticals (MDGL) Receives a Buy from Barclays

Tip Ranks

巴克萊銀行

阿里拉姆制藥

Bridgebio Pharma

拜瑪林制藥

美國銀行

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Madrigal 製藥（MDGL）獲得巴克萊銀行的買入評級